Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Jacobio Pharmaceuticals Group Co., Ltd. ( (HK:1167) ) is now available.
Jacobio Pharmaceuticals has announced the completion of the first patient dosage in the phase I/IIa clinical trial of its pan-KRAS inhibitor JAB-23E73 in the U.S., with a parallel dose-escalation study ongoing in China. This development addresses the significant unmet need for treatments targeting KRAS mutations, which are prevalent in various cancers, and positions Jacobio as a key player in the oncology field with its promising oral KRAS inhibitor showing favorable preclinical results.
The most recent analyst rating on (HK:1167) stock is a Hold with a HK$3.70 price target. To see the full list of analyst forecasts on Jacobio Pharmaceuticals Group Co., Ltd. stock, see the HK:1167 Stock Forecast page.
More about Jacobio Pharmaceuticals Group Co., Ltd.
Jacobio Pharmaceuticals Group Co., Ltd. is a company focused on developing innovative products and solutions to improve patient health, with a pipeline targeting novel molecular targets across six major signaling pathways, including KRAS, immune checkpoints, and tumor metabolism. The company aims to be a global leader in drug R&D, with R&D centers in Beijing, Shanghai, and Boston.
Average Trading Volume: 7,182,131
Technical Sentiment Signal: Buy
Current Market Cap: HK$3.35B
Learn more about 1167 stock on TipRanks’ Stock Analysis page.